ID   ACN
AC   CVCL_1068
DR   CLO; CLO_0001655
DR   CLDB; cl239
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   CCLE; ACN
DR   Cell_Model_Passport; SIDM00057
DR   ChEMBL-Cells; CHEMBL3308148
DR   ChEMBL-Targets; CHEMBL2366195
DR   Cosmic; 906803
DR   Cosmic-CLP; 906803
DR   DepMap; ACH-002389
DR   GDSC; 906803
DR   GEO; GSM1669594
DR   IARC_TP53; 21170
DR   ICLC; HTL96020
DR   LINCS_LDP; LCL-1982
DR   PharmacoDB; ACN_55_2019
DR   Wikidata; Q54608539
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=1354203;
RX   PubMed=2467885;
RX   PubMed=20164919;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (CCLE; Cosmic-CLP).
CC   Sequence variation: Heterozygous for PTEN p.Asn184fs*6 (c.545_546insA) (CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for TP53 p.Phe113Ser (c.338T>C) (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.3%; Native American=0.69%; East Asian, North=0%; East Asian, South=0.16%; South Asian=1.02%; European, North=70.67%; European, South=27.16% (PubMed=30894373).
CC   Derived from metastatic site: Bone marrow.
ST   Source(s): Cosmic-CLP; ICLC
ST   Amelogenin: X
ST   CSF1PO: 11 (Cosmic-CLP)
ST   CSF1PO: 10,11 (ICLC)
ST   D13S317: 11,13
ST   D16S539: 11 (Cosmic-CLP)
ST   D16S539: 10,11 (ICLC)
ST   D21S11: 28
ST   D5S818: 12 (Cosmic-CLP)
ST   D5S818: 11,12 (ICLC)
ST   D7S820: 10,13
ST   TH01: 9 (Cosmic-CLP)
ST   TH01: 8,9 (ICLC)
ST   TPOX: 9,12
ST   vWA: 14,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   3Y3M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 25
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=1354203; DOI=10.1002/ijc.2910520116;
RA   Gross N., Favre S., Beck D., Meyer M.;
RT   "Differentiation-related expression of adhesion molecules and
RT   receptors on human neuroblastoma tissues, cell lines and variants.";
RL   Int. J. Cancer 52:85-91(1992).
//
RX   PubMed=2467885; DOI=10.1002/ijc.2910430421;
RA   Gross N., Beck D., Portoukalian J., Favre S., Carrel S.;
RT   "New anti-GD2 monoclonal antibodies produced from
RT   gamma-interferon-treated neuroblastoma cells.";
RL   Int. J. Cancer 43:665-671(1989).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//